AU2001231006A1 - Statin-type bone growth stimulators - Google Patents
Statin-type bone growth stimulatorsInfo
- Publication number
- AU2001231006A1 AU2001231006A1 AU2001231006A AU3100601A AU2001231006A1 AU 2001231006 A1 AU2001231006 A1 AU 2001231006A1 AU 2001231006 A AU2001231006 A AU 2001231006A AU 3100601 A AU3100601 A AU 3100601A AU 2001231006 A1 AU2001231006 A1 AU 2001231006A1
- Authority
- AU
- Australia
- Prior art keywords
- bone
- compounds
- compound
- alkyl
- heteroaromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/488,380 US6376476B1 (en) | 1996-12-13 | 2000-01-20 | Isoprenoid pathway inhibitors for stimulating bone growth |
US09488380 | 2000-01-20 | ||
PCT/US2001/001888 WO2001052829A2 (fr) | 2000-01-20 | 2001-01-19 | Stimulateurs de croissance osseuse de type statine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001231006A1 true AU2001231006A1 (en) | 2001-07-31 |
Family
ID=23939512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001231006A Abandoned AU2001231006A1 (en) | 2000-01-20 | 2001-01-19 | Statin-type bone growth stimulators |
Country Status (6)
Country | Link |
---|---|
US (4) | US6376476B1 (fr) |
EP (1) | EP1253922A2 (fr) |
JP (1) | JP2003527353A (fr) |
AU (1) | AU2001231006A1 (fr) |
CA (1) | CA2397659A1 (fr) |
WO (2) | WO2001052829A2 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US6410521B1 (en) | 1998-06-12 | 2002-06-25 | Osteoscreen, Inc. | Nutritional supplements for stimulating bone growth |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US7192445B2 (en) * | 2000-12-06 | 2007-03-20 | Astra Tech Ab | Medical prosthetic devices and implants having improved biocompatibility |
JP2002370982A (ja) * | 2001-06-12 | 2002-12-24 | Kowa Co | 骨形成促進剤 |
EP1291017A3 (fr) * | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Utilisation de statines pour prévenir la formation d'osteoclastes |
JP2005527209A (ja) * | 2002-04-22 | 2005-09-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛管理のためのプロテインキナーゼCγのペプチドインヒビター |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
US8876532B2 (en) | 2002-07-31 | 2014-11-04 | Dentsply International Inc. | Bone repair putty |
WO2004091626A1 (fr) * | 2003-04-07 | 2004-10-28 | Osteoscreen, Inc. | Stimulation de la croissance osseuse avec no/statine et autres combinaisons modulatoires |
FI20045223A (fi) * | 2004-06-15 | 2005-12-16 | Bioretec Oy | Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin |
US7250444B2 (en) | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
JP2005060307A (ja) * | 2003-08-12 | 2005-03-10 | Pirumu:Kk | 骨造成剤 |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
GB0327742D0 (en) * | 2003-11-28 | 2003-12-31 | Isis Innovation | Novel uses of known drugs |
US7163945B2 (en) * | 2004-04-29 | 2007-01-16 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US7199126B2 (en) * | 2004-04-29 | 2007-04-03 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US7183285B2 (en) * | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20060084695A1 (en) * | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
EP1591133A1 (fr) * | 2004-04-30 | 2005-11-02 | Synthes | Implants ayant une activité biologique |
US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
US7531518B2 (en) * | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
AU2005331907B2 (en) * | 2004-05-14 | 2010-04-22 | Unigene Laboratories, Inc. | Method for fostering bone formation and preservation |
US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
EP1879608A4 (fr) * | 2005-05-11 | 2009-11-11 | Unigene Lab Inc | Methode pour stimuler la formation et la preservation des os |
US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
EP1996118A4 (fr) * | 2006-03-07 | 2013-03-06 | Osteoscreen Ip Llc | RENFORCEMENT DE L'OS ET DU CARTILAGE PAR UN INHIBITEUR DE LA HMG Co-A RÉDUCTASE |
WO2009093240A2 (fr) * | 2008-01-24 | 2009-07-30 | Ademex Ltd. | Compositions d'érythropoiétine et de fibronectine pour la régénération osseuse |
TWI483726B (zh) * | 2010-01-04 | 2015-05-11 | Food Industry Res & Dev Inst | 新穎吡啶生物鹼、其製備方法及該等吡啶生物鹼之用途 |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
CN102617533B (zh) * | 2011-02-01 | 2014-08-27 | 北京北大维信生物科技有限公司 | 一种从红曲中分离的化合物、其制备方法及用途 |
WO2012170417A2 (fr) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Procédés et compositions pour améliorer la croissance osseuse comprenant une statine |
EP2887932B1 (fr) * | 2012-08-22 | 2020-05-20 | Rosenberg Messina, David Rafael | Utilisation de statines pour une parodontopathie et une régénération osseuse |
CN102885797A (zh) * | 2012-10-29 | 2013-01-23 | 福州海王福药制药有限公司 | 一种含匹伐他汀钙的组合物及其制备方法和应用 |
TWI542569B (zh) * | 2015-02-11 | 2016-07-21 | 高雄醫學大學 | 3,5-二羥基戊酸的類似物用於成骨作用 |
US11065262B2 (en) | 2017-07-27 | 2021-07-20 | Northwestern University | Topical treatment of wounds with statins and cholesterol for scar reduction |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8530603D0 (en) | 1985-12-12 | 1986-01-22 | Leo Pharm Prod Ltd | Chemical compounds |
US5021451A (en) * | 1988-11-14 | 1991-06-04 | Hoffman-La Roche Inc. | Method for inhibiting hyperproliferative diseases |
US5093363A (en) | 1989-08-22 | 1992-03-03 | Shionogi & Co., Ltd. | 2,4,6-substituted phenol derivatives |
US5316765A (en) | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
US5258376A (en) | 1989-11-22 | 1993-11-02 | Bernstein Lawrence R | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
US5128366A (en) | 1990-07-05 | 1992-07-07 | Shinogi & Co., Ltd. | Pyrrole derivatives |
JPH05163150A (ja) | 1991-05-13 | 1993-06-29 | E R Squibb & Sons Inc | アテローム性動脈硬化症の抑制・治療剤 |
DK0554455T3 (da) | 1991-06-19 | 1998-01-19 | Shionogi & Co | Optisk aktivt mellemprodukt og fremstilling deraf |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
ES2151508T3 (es) * | 1992-05-13 | 2001-01-01 | Us Health | Empleo de inhibidores de reductasa 3-hidroxi-3-metilglutaril coenzima a como una modalidad en la terapia del cancer. |
US5278153A (en) * | 1992-05-18 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method |
EP0619305B1 (fr) | 1993-02-05 | 1997-06-04 | Teijin Limited | Composé du type lactone et procédé pour leur préparation |
US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5403829A (en) | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
US5336687A (en) | 1993-08-04 | 1994-08-09 | American Home Products Corporation | Inhibition of bone loss by 4-aryloxy-5-hydroxy-2(5H)-furanones |
US5462932A (en) | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
JP3566984B2 (ja) | 1994-06-02 | 2004-09-15 | 帝人株式会社 | 骨形成促進剤 |
US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
WO1996019501A1 (fr) * | 1994-12-20 | 1996-06-27 | Osteosa Inc. | Modulateurs des fonctions des cellules osseuses et leurs utilisations |
US5545661A (en) | 1995-05-16 | 1996-08-13 | Eli Lilly And Company | Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds |
US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
HUP9802319A3 (en) | 1995-10-23 | 1999-12-28 | Zymogenetics Inc Seattle | Pharmaceutical compositions for treatment of bone deficit conditions |
JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
US5935607A (en) | 1996-02-15 | 1999-08-10 | Hadasit Medical Research Services And Development Company Ltd. | Treatment of osteoporosis |
US5902805A (en) * | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
JP2000514048A (ja) | 1996-06-20 | 2000-10-24 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 薬理学的活性調製物を提供するための化合物および方法ならびにそれらの使用 |
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
US5965573A (en) * | 1996-10-23 | 1999-10-12 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
WO1998017267A1 (fr) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions et methodes pour traiter les etats associes a un deficit osseux |
US5840752A (en) * | 1996-11-21 | 1998-11-24 | Henry; James P. | Reduction of hair growth |
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
WO1998025460A1 (fr) * | 1996-12-13 | 1998-06-18 | Zymogenetics, Inc. | Compositions visant a stimuler la croissance osseuse et methodes afferentes |
WO1999045923A1 (fr) | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Methodes visant a bloquer la resorption osseuse |
JP4592127B2 (ja) * | 1999-03-30 | 2010-12-01 | 雪印乳業株式会社 | 骨吸収抑制剤 |
WO2001037876A2 (fr) | 1999-11-24 | 2001-05-31 | Bayer Aktiengesellschaft | Procedes d'amelioration de conditions osseuses anormales |
EP1322306A2 (fr) * | 2000-09-19 | 2003-07-02 | NovImmune S.A. | Statines (inhibiteurs de la hmg-coa reductase) en tant que nouveau type d'agent immunomodulateur, immunosuppresseur et anti-inflammatoire |
US20030229044A1 (en) * | 2002-03-29 | 2003-12-11 | Lawrence Steinman | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
WO2003105752A2 (fr) * | 2002-05-02 | 2003-12-24 | Osteoscreen, Inc. | Procedes et compositions stimulant la croissance osseuse a l'aide de l'oxyde nitrique liberant des conjugues de bisphosphonate |
-
2000
- 2000-01-20 US US09/488,380 patent/US6376476B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 JP JP2001552877A patent/JP2003527353A/ja active Pending
- 2001-01-19 CA CA002397659A patent/CA2397659A1/fr not_active Abandoned
- 2001-01-19 WO PCT/US2001/001888 patent/WO2001052829A2/fr not_active Application Discontinuation
- 2001-01-19 EP EP01903155A patent/EP1253922A2/fr not_active Withdrawn
- 2001-01-19 AU AU2001231006A patent/AU2001231006A1/en not_active Abandoned
- 2001-04-02 WO PCT/US2001/040421 patent/WO2001074180A1/fr not_active Application Discontinuation
- 2001-05-03 US US09/848,839 patent/US6642216B2/en not_active Expired - Lifetime
-
2003
- 2003-08-29 US US10/652,159 patent/US7101907B2/en not_active Expired - Fee Related
-
2005
- 2005-06-24 US US11/167,054 patent/US20050272801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040106675A1 (en) | 2004-06-03 |
CA2397659A1 (fr) | 2001-07-26 |
US7101907B2 (en) | 2006-09-05 |
WO2001074180A1 (fr) | 2001-10-11 |
US6642216B2 (en) | 2003-11-04 |
WO2001052829A2 (fr) | 2001-07-26 |
US6376476B1 (en) | 2002-04-23 |
US20010034364A1 (en) | 2001-10-25 |
EP1253922A2 (fr) | 2002-11-06 |
JP2003527353A (ja) | 2003-09-16 |
WO2001052829A3 (fr) | 2002-05-02 |
US20050272801A1 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001231006A1 (en) | Statin-type bone growth stimulators | |
US6080779A (en) | Compositions and methods for stimulating bone growth | |
AU729793B2 (en) | Compositions and methods for stimulating bone growth | |
US6342514B1 (en) | Compositions and methods for treating bone deficit conditions | |
US5994358A (en) | Compositions and methods for treating bone deficit conditions | |
US6153631A (en) | Compositions and methods for treating bone deficit conditions | |
US5922753A (en) | Methods for treating bone deficit conditions with benzothiazole | |
US5919808A (en) | Compositions and methods for treating bone deficit conditions | |
US6462019B1 (en) | Inhibitors of proteasomal activity and production for stimulating bone growth | |
US5948776A (en) | Compositions and methods for treating bone deficit conditions | |
US5965573A (en) | Compositions and methods for treating bone deficit conditions | |
AU706262B2 (en) | Compositions and methods for treating bone deficit conditions | |
WO1998025460A9 (fr) | Compositions visant a stimuler la croissance osseuse et methodes afferentes | |
US6656904B2 (en) | Inhibitors of proteasomal activity for stimulating bone and hair growth | |
US6413998B1 (en) | Compositions and methods for treating bone deficit conditions | |
WO1997015308A9 (fr) | Compositions et procedes pour le traitement des deficits osseux | |
US20040254238A1 (en) | Bone growth stimulation with NO/statin and other NO modulating combinations | |
US6410521B1 (en) | Nutritional supplements for stimulating bone growth | |
US20030181374A1 (en) | Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly | |
US5939444A (en) | Compositions and methods for treating bone deficit conditions | |
US6017940A (en) | Compositions and methods for treating bone deficit conditions | |
EP1609469A2 (fr) | Compositions et méthodes pour stimuler la croissance osseuse | |
EP1267641A1 (fr) | Supplements nutritionnels pour stimuler la croissance osseuse |